Find comprehensive information on Transcatheter Aortic Valve Replacement TAVR medical coding, ICD-10 codes, clinical documentation requirements, and healthcare procedures. This resource covers TAVR diagnosis, treatment, post-operative care, and coding guidelines for accurate reimbursement. Learn about aortic stenosis, valve replacement procedures, and best practices for clinical documentation improvement CDI related to TAVR. Explore resources for physicians, coders, and healthcare professionals involved in TAVR patient care.
Also known as
Insertion of aortic valve prosthesis
Transcatheter aortic valve replacement/implantation.
Aortic stenosis
Narrowing of the aortic valve opening, often treated with TAVR.
Rheumatic aortic stenosis
Aortic valve narrowing due to rheumatic fever, sometimes requiring TAVR.
Nonrheumatic aortic stenosis
Aortic valve narrowing not caused by rheumatic fever, may need TAVR.
Follow this step-by-step guide to choose the correct ICD-10 code.
Was TAVR performed?
Yes
Initial or subsequent procedure?
No
Do not code TAVR. Review documentation for alternative diagnosis.
When to use each related code
| Description |
|---|
| Transcatheter Aortic Valve Replacement |
| Aortic Valve Stenosis |
| Surgical Aortic Valve Replacement |
Incorrect coding of the specific TAVR device used, leading to inaccurate reimbursement and data reporting. Focus on ICD-10-PCS and HCPCS code accuracy.
Insufficient physician documentation of the TAVR procedure, including pre- and post-procedure diagnoses, complications, and device specifics, hindering accurate coding.
Incorrect assignment of the principal diagnosis, such as aortic stenosis, impacting DRG assignment, quality metrics, and reimbursement. CDI crucial for specificity.
Q: What are the latest evidence-based best practices for patient selection in transcatheter aortic valve replacement (TAVR) for intermediate-risk patients?
A: Patient selection for TAVR in intermediate-risk individuals requires a multidisciplinary heart team approach and careful consideration of various factors beyond just surgical risk. The current guidelines, including those from the American College of Cardiology (ACC) and the American Heart Association (AHA), recommend evaluating factors such as frailty, anatomical suitability (e.g., access vessel size, annular dimensions), comorbidities, and patient preferences. Consider implementing a standardized evaluation protocol incorporating frailty assessment tools like the Katz Index of Independence in Activities of Daily Living and a comprehensive assessment of coronary anatomy. Explore how the Society of Thoracic Surgeons (STS) risk score, combined with other clinical factors, can help refine patient selection and predict outcomes. Learn more about the latest clinical trials comparing TAVR and surgical aortic valve replacement (SAVR) in intermediate-risk patients to further inform decision-making.
Q: How can clinicians effectively manage and mitigate common post-TAVR complications like paravalvular leak (PVL) and conduction abnormalities requiring permanent pacemaker implantation (PPI)?
A: Managing post-TAVR complications requires meticulous pre-procedural planning and proactive post-procedural surveillance. For paravalvular leak (PVL), careful valve sizing and positioning during the procedure are critical. Post-procedure, echocardiography is essential for assessment. Moderate to severe PVL may necessitate intervention, which can range from optimized medical therapy to percutaneous closure devices. Regarding conduction abnormalities, pre-procedural electrocardiograms and careful assessment of the conduction system during TAVR can help anticipate the need for PPI. Consider implementing strategies to minimize atrioventricular block during the procedure. Explore the latest research on the predictors of PPI in TAVR patients and learn more about optimal pacemaker programming post-implantation.
Transcatheter aortic valve replacement (TAVR) was performed on [Date] for severe symptomatic aortic stenosis. The patient presented with [Symptoms e.g., dyspnea, angina, syncope] and was deemed high-risk for conventional surgical aortic valve replacement (SAVR) due to [Comorbidities e.g., advanced age, frailty, prior cardiac surgery, severe lung disease]. Pre-procedural evaluation included transthoracic echocardiogram (TTE) demonstrating [TTE Findings e.g., severe aortic stenosis, mean gradient of [Gradient Value] mmHg, aortic valve area of [AVA Value] cm2, left ventricular ejection fraction (LVEF) of [LVEF Value] %]. Computed tomography (CT) angiography confirmed suitability for transfemoral access. The procedure was performed under [Anesthesia Type e.g., conscious sedation, general anesthesia] using a [Valve Type e.g., balloon-expandable, self-expanding] transcatheter heart valve. The valve was successfully deployed via the [Access Site e.g., transfemoral, transapical, transaortic] approach. Post-deployment angiography showed [Angiographic Findings e.g., excellent valve function, no paravalvular leak, trace aortic regurgitation]. Hemodynamics improved significantly post-TAVR. The patient tolerated the procedure well and was transferred to [Post-Procedure Location e.g., post-anesthesia care unit, cardiac intensive care unit] in stable condition. Diagnosis: Aortic valve stenosis, severe. Procedure: Transcatheter aortic valve implantation (TAVI), [Access Site] approach. Plan: Post-TAVR care, cardiac rehabilitation, follow-up echocardiography.